Researchers at the University of Cologne and University Hospital Cologne have determined that the novel mRNA-based COVID-19 vaccines not only induce acquired immune responses such as antibody ...
Phase 2 IND submission targeted for the second half of 2026- Demonstrating the competitiveness of GC Biopharma's mRNA platform YONGIN, South Korea, Dec. 22, 2025 /PRNewswire/ -- GC Biopharma (006280 ...
The same groundbreaking technology that enabled rapid COVID-19 vaccine development is now poised to revolutionize medicine in ways that seemed impossible just a few years ago. Messenger RNA vaccines ...
Stanford scientists have uncovered how mRNA COVID-19 vaccines can very rarely trigger heart inflammation in young men — and ...
Messenger RNA technology, better known as mRNA technology, made it possible to rapidly deploy a new vaccine during the COVID-19 pandemic — much earlier than would otherwise have been possible, saving ...
WASHINGTON (AP) — So-called mRNA vaccines saved millions of lives during the COVID-19 pandemic — and now scientists are using that Nobel Prize-winning technology to try to develop vaccines and ...
Stanford researchers identified a two-step immune process causing rare myocarditis after mRNA COVID-19 vaccines, primarily in ...
Health and Human Services Secretary Robert F. Kennedy Jr. revealed his agency will be cutting funding to mRNA development, calling the vaccine technology "ineffective" and claiming it poses more risks ...
Flu vaccines that take a page from the COVID-19 vaccine platform are making progress in clinical trials. In a phase 3 trial, Pfizer’s mRNA flu vaccine outperformed a traditional vaccine, researchers ...
Innorna today announced the completion of enrollment and vaccination in its Phase II clinical trial for IN006, the world’s first bivalent respiratory syncytial virus (RSV) mRNA vaccine currently in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback